REG - CVS Group plc - Director/PDMR Shareholding

CVSAnnouncement

05/01/2024 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240105:nRSE8026Ya&default-theme=true

RNS Number : 8026Y  CVS Group plc  05 January 2024

5 January 2024

 

CVS Group Plc

("CVS" or the "Company")

Exercise of Options, PDMR Dealing

and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services,
announces that on 4 January 2023, options over a total of 148,032 ordinary
shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS
Group 2020 SAYE Plan (2020/2024) and 6,733 Ordinary Shares under the CVS Group
Long Term Incentive Plan 2020 ("LTIP 14").

The sum of 148,032 new Ordinary Shares were issued to satisfy the balance of
Ordinary Shares arising from the SAYE Exercise at an exercise price of
£10.09.  Admission of the 148,032 new Ordinary Shares has been satisfied by
the Company's block listing admitted to the London Stock Exchange on 30
December 2021.

Robin Alfonso, Chief Financial Officer exercised options over 606 Ordinary
Shares in the Company under the SAYE plan. The balance of the options were
exercised by certain other employees and former employees of the Company.

Robin Alfonso additionally exercised options over 6,733 Ordinary Shares under
the LTIP 14 scheme. The issuance of shares in connection with the LTIP 14
exercise was fully satisfied by 6,733 Ordinary Shares held by the CVS Group
Employee Benefit Trust (the "EBT").  Following the exercise, a total of
47,945 Ordinary Shares are held by the EBT, representing approximately 0.067%
of the Company's total voting rights.

Following his option exercises, Robin Alfonso holds a beneficial interest in
19,896 Ordinary Shares in the Company, representing approximately 0.028% of
the total voting rights of the Company, calculated on the same basis.

Following the issue of the new Ordinary Shares, the Company has a total issued
share capital of 71,685,694 Ordinary Shares each carrying one voting right.
The Company holds no Ordinary Shares in treasury. Therefore, following the
issue of the new Ordinary Shares, the total number of voting rights in the
Company will be 71,685,694. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

Contacts:

CVS Group
plc
via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser &
Broker)
+44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

 

   Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial
PR)

Geoffrey
Pelham-Lane
                     +44 (0)7733 124 226

Ginny
Pulbrook
+44 (0)7961 315 138

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                      Robin Alfonso
 2   Reason for the notification
 a)  Position/status                           Chief Financial Officer
 b)  Initial notification /Amendment           Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                      CVS Group plc
 b)  LEI                                       213800J41XDQ2NX48O05
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted

 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.2 pence each

     Identification code                                          GB00B2863827
 b)  Nature of the transaction                                    a)   Exercise of options under the 2020 SAYE Plan (1 January 2024 maturity)

                                                                  b)   Exercise of options under the CVS Group Long Term Incentive Plan 2020
                                                                  (4 January 2024 maturity)

 c)  Price(s) and volume(s)                                       Price(s)         Volume
                                                                  a)   £10.09      a)   606

                                                                  b)   £0.002      b)   6,733

 

 

 

 d)  Aggregated information

     - Aggregated volume

                                                                  7,339

     - Price

                                                                  £6,128.01
 e)  Date of the transaction                                      a)   4 January 2023

                                                                  b)   4 January 2023
 f)  Place of the transaction                                     a)   London Stock Exchange - AIM

                                                                  b)   London Stock Exchange - AIM

 

 

d)

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

7,339

 

 

£6,128.01

e)

Date of the transaction

a)   4 January 2023

b)   4 January 2023

f)

Place of the transaction

a)   London Stock Exchange - AIM

b)   London Stock Exchange - AIM

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAEFSEFNLEFA